A method for modulating cellular activity in a subject, consisting essentially of the steps: (i) forming a liquid composition, (ii) subjecting the liquid composition to sequential harmonic oscillation to provide a liquid biochemical scaffold and, (iii) delivering a therapeutically effective amount of said liquid biochemical scaffold to said subject.

The present invention relates to an anti-inflammatory composition and a composition for treatment of an inflammatory disease, both comprising a composite plant extract and, more particularly, to an anti-inflammatory composition comprising a composite plant extract including a Perilla frutescens extract and an Atractylodes macrocephala Koidzumi extract; a preparation method thereof; and a pharmaceutical composition comprising the composite extract for treatment of an inflammatory disease.

The present invention relates to an anti-inflammatory composition and a composition for treatment of an inflammatory disease, both comprising a composite plant extract and, more particularly, to an anti-inflammatory composition comprising a composite plant extract including a Perilla frutescens extract and an Atractylodes macrocephala Koidzumi extract; a preparation method thereof; and a pharmaceutical composition comprising the composite extract for treatment of an inflammatory disease.

A biochemical scaffold for regulating mammalian cell function, including a bioenergetic platform and a vibrational platform, the bioenergetic platform comprising a Krebs cycle modulator and/or glutathione modulator and/or neurotransmitter modulator and/or DNA modulator and/or endocannabinoid system modulator, the vibrational platform comprising at least one energy signature component, e.g., herb, that is subjected to continued or steady state harmonic oscillation at a frequency in the range of approximately 23 Hz-1000 GHz for a period of time in the range of approximately 3-48 hrs. or sequential harmonic oscillation at frequencies in the range of approximately 0.9 kHz-1.5 kHz for a period of time in the range of approximately 3-60 minutes, approximately 9.5 kHz-10.5 kHz for a period of time in the range of approximately 3-60 minutes, approximately 9.5 kHz-11.0 kHz for a period of time in the range of approximately 3-60 minutes, approximately 0.01 kHz-0.03 kHz for a period of time in the range of approximately 3-60 minutes, and approximately 0.004 kHz-0.010 kHz for a period of time in the range of approximately 3-60 minutes.

A biochemical scaffold for regulating mammalian cell function, including a bioenergetic platform and a vibrational platform, the bioenergetic platform comprising a Krebs cycle modulator and/or glutathione modulator and/or neurotransmitter modulator and/or DNA modulator and/or endocannabinoid system modulator, the vibrational platform comprising at least one energy signature component, e.g., herb, that is subjected to continued or steady state harmonic oscillation at a frequency in the range of approximately 23 Hz-1000 GHz for a period of time in the range of approximately 3-48 hrs. or sequential harmonic oscillation at frequencies in the range of approximately 0.9 kHz-1.5 kHz for a period of time in the range of approximately 3-60 minutes, approximately 9.5 kHz-10.5 kHz for a period of time in the range of approximately 3-60 minutes, approximately 9.5 kHz-11.0 kHz for a period of time in the range of approximately 3-60 minutes, approximately 0.01 kHz-0.03 kHz for a period of time in the range of approximately 3-60 minutes, and approximately 0.004 kHz-0.010 kHz for a period of time in the range of approximately 3-60 minutes.

A biochemical scaffold for regulating mammalian cell function, including a bioenergetic platform and a vibrational platform, the bioenergetic platform comprising a Krebs cycle modulator and/or glutathione modulator and/or neurotransmitter modulator and/or DNA modulator and/or endocannabinoid system modulator, the vibrational platform comprising at least one energy signature component, e.g., herb, that is subjected to continued or steady state harmonic oscillation at a frequency in the range of approximately 23 Hz-1000 GHz for a period of time in the range of approximately 3-48 hrs. or sequential harmonic oscillation at frequencies in the range of approximately 0.9 kHz-1.5 kHz for a period of time in the range of approximately 3-60 minutes, approximately 9.5 kHz-10.5 kHz for a period of time in the range of approximately 3-60 minutes, approximately 9.5 kHz-11.0 kHz for a period of time in the range of approximately 3-60 minutes, approximately 0.01 kHz-0.03 kHz for a period of time in the range of approximately 3-60 minutes, and approximately 0.004 kHz-0.010 kHz for a period of time in the range of approximately 3-60 minutes.

The present disclosure relates to a pharmaceutical composition for preventing and treating senile dementia and preparation method thereof. The active ingredients of the pharmaceutical composition are prepared from raw medicinal materials comprising 20-50 parts by weight of Epimedii Folium and 15-55 parts by weight of Poria; or from raw medicinal materials comprising 20-50 parts by weight of Epimedii Folium, 15-55 parts by weight of Poria and 10-55 parts by weight of Acanthopanax, or from raw medicinal materials comprising 20-50 parts by weight of Epimedii Folium, 15-50 parts by weight of Poria, 15-50 parts by weight of Acanthopanax and 6-15 parts by weight of Anemarrhenae Rhizoma.

The present disclosure relates to a pharmaceutical composition for preventing and treating senile dementia and preparation method thereof. The active ingredients of the pharmaceutical composition are prepared from raw medicinal materials comprising 20-50 parts by weight of Epimedii Folium and 15-55 parts by weight of Poria; or from raw medicinal materials comprising 20-50 parts by weight of Epimedii Folium, 15-55 parts by weight of Poria and 10-55 parts by weight of Acanthopanax, or from raw medicinal materials comprising 20-50 parts by weight of Epimedii Folium, 15-50 parts by weight of Poria, 15-50 parts by weight of Acanthopanax and 6-15 parts by weight of Anemarrhenae Rhizoma.

The present disclosure relates to a pharmaceutical composition for preventing and treating senile dementia and preparation method thereof. The active ingredients of the pharmaceutical composition are prepared from raw medicinal materials comprising 20-50 parts by weight of Epimedii Folium and 15-55 parts by weight of Poria; or from raw medicinal materials comprising 20-50 parts by weight of Epimedii Folium, 15-55 parts by weight of Poria and 10-55 parts by weight of Acanthopanax, or from raw medicinal materials comprising 20-50 parts by weight of Epimedii Folium, 15-50 parts by weight of Poria, 15-50 parts by weight of Acanthopanax and 6-15 parts by weight of Anemarrhenae Rhizoma.

A pretreatment herbal composition comprises Andrographis paniculata, Eleuthero roots, and resistant potato starch. A treatment herbal composition comprises cannabidiol, bee pollen, and coconut oil, and in some embodiments, additionally comprises hemp seed oil. A fortifying herbal composition comprises many ingredients. A method comprises the steps of providing a dose of apitoxin at least once a day for at least one day, providing a dose of a glucosamine product at least once a day for at least one day, and providing a dose of a treatment herbal composition at least once a day for at least one day. In some embodiments, the method additionally comprises the step of providing a dose of a pretreatment herbal composition at least once a day for at least one day. In further embodiments, the method additionally comprises the step of providing a dose of a fortifying herbal composition.